Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Montana hearing on House Bill 783: sponsors and medical groups urge insurer coverage for GLP‑1 weight‑loss drugs; insurers warn of large fiscal impact
Summary
Representative Scott Rosenzweig and physician and advocacy witnesses urged coverage of GLP‑1 drugs for a narrowly defined group of patients with class‑3 obesity and PCOS, while insurer witnesses warned the mandate would substantially increase premiums and state reimbursement costs.
Representative Scott Rosenzweig (R‑House District 57) opened a hearing on House Bill 783, asking the committee to require insurers to cover glucagon‑like peptide‑1 (GLP‑1) weight‑loss drugs like Ozempic and Wegovy for patients with “type 3” or class‑3 obesity (body‑mass index of 40 or more) and certain severe weight‑related conditions, and to include polycystic ovary syndrome (PCOS) as a qualifying diagnosis.
Rosenzweig told the committee the bill is intended to allow doctors to prescribe GLP‑1s before patients develop type‑2 diabetes. “These drugs are expensive,” he said, and he cited widely varying prices between countries; he told members a fiscal note was still being worked out and “looks like it will cost the state somewhere between $1 and…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
